- The FDA has signed off Xeris Pharmaceuticals Inc's XERS Investigational New Drug Application (IND) for its XeriSol levothyroxine (XP-8121) for hypothyroidism.
- Xeris will initiate a Phase 1 study to characterize Pharmacokinetics (PK) and evaluate the safety and tolerability of XP-8121 in healthy participants.
- Price Action: XERS shares are up 21.7% at $2.86 during the premarket session on the last check Thursday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
